endoscope between the two procedures, is a variation of endoscopic shuffling that, additionally, is contraindicated by published endoscope reprocessing guidelines and the manufacturer’s reprocessing instructions.10,17

2. Purchase a sufficient number of appropriate types and models of both upper and lower GI endoscopes to accommodate patient demand and avoid endoscopic shuffling.18

A. Purchase of a push enteroscope, for example, is recommended if a GI endoscopy unit intends to perform push enteroscopy.

B. Perform each GI endoscopic procedure using the specific type and model of GI endoscope labeled and intended for the procedure.

C. If the type and model of GI endoscope indicated for a specific procedure is not available, consider referring the patient to another GI endoscopy unit that has the GI endoscope in inventory and available for use.

D. A request for more funding to purchase additional upper and lower GI endoscopes as required to meet patient demand may be necessary.

3. Under some circumstances, endoscopic shuffling may be acceptable, provided data are available that indicate it is likely to improve the clinical outcome and optimize patient care.

A. Push enteroscope has been reported to improve the clinical outcome and, for example, prevent incomplete or unsuccessful colonoscopy.3,7

B. Retain on file the studies, reports, and published data that support the safety, effectiveness, and clinical benefit of the off-label application of endoscopic shuffling.

C. Dedicate and clearly mark, or label, any GI endoscope subject to endoscopic shuffling.

   (a) Marking, for example, a colonoscope exclusively for use during push enteroscopy, instead of using the colonoscope interchangeably during both upper and lower GI procedures, eliminates the risk of fecal-oral disease transmission.

D. Ensure endoscopic shuffling is performed with care and caution and only by GI endoscopists trained in the use of a lower or upper GI endoscope in the upper or lower GI tract, respectively.

4. As with all types of reusable instruments, reprocess upper and lower GI endoscopes in strict accordance with both published guidelines and their respective manufacturers’ reprocessing instructions.10,17

A. Clean, high-level disinfect (and water rinse), and dry GI endoscopes after each endoscopic procedure (not after each patient sitting, during which time more than one GI endoscopic procedure may be performed using the same endoscope; refer to section 1.E.c. above).

B. The endoscope ordinarily does not require reprocessing upon its removal from storage and immediately prior to its first use of the day.18

   (a) Only under a limited number of circumstances would reprocessing the endoscope before the first patient of the day be indicated.18 (Refer to the June, 2000, issue of this newsletter.)

C. Consider asking patients not to ingest foods containing Olestra, or a similar type of dietary fat substitute, or to take “fat-blocking” drugs such as orlistat (Xenical), several days prior to scheduled lower GI endoscopy.

   (a) Consider using detergents that have been shown during simulated in-use studies to facilitate removal of all types of patient debris, including fats and Olestra and other dietary fat substitutes, from all of the GI endoscope’s surfaces, including its valves, during cleaning and endoscope reprocessing. The End 7 LFM

---

**Critique of a FDA-CDC health advisory**

Lessons taught in a recent series of articles published in this newsletter in 2005 question the conclusion of a FDA-CDC public health advisory that discusses endoscope reprocessing.20 These lessons can be applied to, and used to identify the mode of transmission of, most true and pseudo outbreaks linked to bronchoscopes.

A FDA-CDC public health advisory entitled “Infections from endoscopes inadequately reprocessed by an automated endoscope reprocessing system” provides several recommendations to prevent true and pseudo infections associated with bronchoscopes improperly reprocessed using automated endoscope reprocessors or an automated system.20 For example, this health advisory recommends that healthcare staff members compare, and resolve any conflicting instructions between, the reprocessing instructions provided by the manufacturers of both the endoscope and the automated endoscope reprocessor or system.20 In addition to bronchoscopes, this advisory’s recommendations apply to gastrointestinal (GI) endoscopes, ear-nose-and-throat ("ENT") endoscopes, and other types of flexible endoscopes.

The purpose for the issuance of this FDA-CDC health advisory was to publicize specific reprocessing breeches that reportedly were responsible for three clusters of respiratory specimens contaminated with *Mycobacterium tuberculosis,* *M. avium-intracellulare* (MAI), and imipenem-resistant *Pseudomonas aeruginosa* (IRPA), respectively.20-22 All three of these clusters were associated with the use of a specific automated system labeled to “sterilize” bronchoscopes, and, according to this health advisory, were a result of apparent

(Continued on page 4)
“patient-to-patient transmission.” The investigation of each of these three clusters was summarized in a report referenced by this advisory and previously published by the CDC in *Morbidity and Mortality Weekly Report (MMWR).*

- The first of these three clusters, referred to in this *MMWR* as *cluster 1,* describes five patients whose respiratory specimens were contaminated with *M. tuberculosis.* Only one of these five patients displayed clinical evidence of tuberculosis. The respiratory specimens of these five patients were collected using three bronchoscopes that were reprocessed using an automated system (whose manufacturer assisted in the investigation).

- The second cluster, referred to in this *MMWR* as *cluster 2,* describes seven patients whose respiratory specimens were contaminated with MAI. None of the patients displayed clinical evidence of infection of MAI. The respiratory specimens of these seven patients were collected using one bronchoscope that was reprocessed using the same automated system associated with *cluster 1.*

- The third cluster, referred to in this *MMWR* as *cluster 3,* describes 18 patients whose respiratory specimens were contaminated with IRPA. Three of these 18 patients displayed clinical symptoms of IRPA infection following bronchoscopy. One month earlier, the medical facility changed its reprocessing procedure and began reprocessing bronchoscopes using the same automated system associated with *clusters 1* and *2.* An article that provides a more detailed discussion of this incident than reported in this *MMWR* was published last year in this newsletter.

A series of five articles that discusses contaminated respiratory specimens associated with true and pseudo outbreaks was published last year in this newsletter (*refer to the January through October 2005 issues*). This series focuses on the modes of transmission associated with gram-negative bacteria, such as *P. aeruginosa,* and both atypical and tuberculous mycobacteria. The lessons taught in this series of articles were studied and applied to this FDA-CDC health advisory (and to the physicians’ conclusion), to evaluate the validity of its claim that the mode of transmission associated with each of these three clusters was patient-to-patient.

The results of this study refute this health advisory’s conclusion and suggest not only that both *clusters 1* and *2* were pseudo outbreaks, but that *cluster 3* was a true and pseudo outbreak, the sources of which may have been the environment in addition to, or in lieu of, an index patient. First, *cluster 1* describes four patients not displaying symptoms of tuberculosis, suggesting that this incident is a pseudo outbreak of *M. tuberculosis*—not, as the health advisory suggests, a true outbreak of *M. tuberculosis* due to patient-to-patient transmission. As reported in the *MMWR,* environmental contamination occurring in the microbiology laboratory may have been responsible for *cluster 1.*

Second, none of *cluster 2’s* seven patients displayed clinical evidence of MAI infection. Moreover, as thoroughly discussed last year in several of this newsletter’s articles, reports of patient-to-patient transmission of atypical mycobacteria, including MAI, via a bronchoscope are lacking. This finding leads to the conclusion that *cluster 2* most likely describes a pseudo outbreak of MAI caused by environmental contamination of the respiratory specimens—not, as the health advisory suggests, a true outbreak of MAI due to patient-to-patient transmission. If *cluster 2* were to describe a true outbreak of MAI due to patient-to-patient transmission via a contaminated bronchoscope, it would be one of the very few cases reported in the medical literature.

And, third, the FDA-CDC health advisory’s conclusion that the mode of transmission of *cluster 3* was (exclusively) patient-to-patient is questioned for a number of reasons. First, as reported by physicians investigating this outbreak, *cluster 3* describes both a true and pseudo outbreak of IRPA, indicating that at least some of the respiratory specimens were contaminated by the environment and not due to cross-infection. Second, these physicians published that neither an index patient nor “patient-to-patient transmission” of IRPA was identified, notwithstanding the advisory’s conclusion about *cluster 3.* And, finally, IRPA is a gram-negative bacterium that, like MAI (*cluster 2*), is opportunistic and has been cultured in the environment. Therefore, the possibility exists not only that the environment was a source of both *cluster 3’s* true and pseudo outbreaks, but that the mode of transmission of *cluster 3’s* true outbreak was environment-to-patient, not patient-to-patient.

References for the 2 articles in this series are available at: [http://www.myendosite.com/refs010206.htm](http://www.myendosite.com/refs010206.htm)

Thank you for your interest in this newsletter. I have addressed each issue to the best of my ability. Respectfully, the Publisher: Lawrence F. Muscarella, Ph.D. Please direct all correspondence to:

Lawrence F. Muscarella, Ph.D.
Editor-in-Chief, The Q-Net™ Monthly Director, Research and Development

Custom Ultrasonics, Inc.
144 Railroad Drive, Ivyland, PA 18974
Telephone: 215.364.8577; Fax: 215.364.7674
E-mail: editor@myendosite.com
Internet: [http://www.myendosite.com](http://www.myendosite.com)

Copyright © 1995-2006. All rights reserved. It is a violation of federal copyright laws (17 U.S.C. Sec. 101 et seq.) to copy, fax, or reproduce any portion of this newsletter without its editor’s consent. Q-Net is a registered trademark of Custom Ultrasonics, Inc.